VANCOUVER, BC, Canada -- April 29, 2021 -- InvestorsHub NewsWire
-- Today, Rakovina Therapeutics announced the formation of its
inaugural Scientific Advisory Board. Made up of experts in biology,
medicinal chemistry and pharmacology, the Scientific Advisory Board
will contribute to Rakovina Therapeutics' development of new cancer
treatments informed by the latest scientific research, and
practical and clinical perspectives.
"We are thrilled to have such a talented and experienced
scientific advisory board providing critical expertise to our
team", said Jeffrey Bacha, Rakovina Therapeutics executive
chairman. "Rakovina Therapeutics will benefit from their
invaluable input as we advance our pipeline of novel oncology
assets."
Rakovina Therapeutics is committed to advancing new cancer
treatments based on novel DNA-damage response technologies.
Under the advisement of the Scientific Advisory Board, made up of
world-class experts who have been directly involved in the
successful development of multiple life-saving cancer treatments,
Rakovina Therapeutics aims to develop innovative therapies for a
range of cancer indications.
"Rakovina Therapeutics aims to become a leader in the
development of new medicines in the fast-moving DNA-damage response
field," said Prof. Mads Daugaard, Rakovina Therapeutics'
president and chief scientific officer. "Working with our
distinguished Scientific Advisory Board allows us to deepen
our commitment to conducting leading edge scientific research and
developing best-in-class cancer therapeutics, ultimately benefiting
cancer patients and their families."
The inaugural members of the Rakovina Therapeutics
scientific advisory board include:
Dennis Brown, PhD has been involved in
cancer drug discovery and development for more than 35 years.
Initially with the Stanford Research Institute at Stanford
University where he was involved in drug-screening activities
sponsored by the US National Cancer Institute. Dr. Brown has
founded or co-founded multiple companies including Matrix
Pharmaceutical, Inc. (acquired by Chiron Corp. in 2002), Mountain
View Pharmaceuticals, ChemGenex Pharmaceuticals (acquired by
Cephalon/Teva in 2011) and Kintara Therapeutics, Inc. (NASDAQ:
KTRA, formerly DelMar Pharmaceuticals). During his career, Dr.
Brown has been involved in the discovery and development of
multiple FDA-approved cancer therapies. He currently serves as a
member of the National Brain Tumor Society Research Roundtable, as
a consultant to DelMar Pharmaceuticals, as Chairman of Mountain
View Pharmaceutical's Board of Directors and is the President of
Valent Technologies LLC, which supported the discovery and
development of Edison Oncology's drug candidates. Dr. Brown served
as an Assistant Professor of Radiology at Harvard University
Medical School and as a Research Associate in Radiology
at Stanford University Medical School. He received his
B.A. in Biology and Chemistry (1971), M.S. in Cell Biology (1975)
and Ph.D. in Radiation and Cancer Biology (1979), all from New
York University. Dr. Brown is an inventor of more than 40 issued
U.S. patents and applications, many with foreign counterparts.
Leonard Post, PhD brings more than 35
years of drug development and leadership experience in the
pharmaceutical and biotechnology industry spanning companies of all
sizes. He currently serves as member of the board of directors and
chief scientific officer of Vivace Pharmaceuticals. Previously, he
served as chief scientific officer of BioMarin, a publicly held
biopharmaceutical firm with a focus on rare diseases. He joined
BioMarin when the company acquired LEAD Therapeutics, where he was
chief scientific officer and responsible for the development of the
blockbuster PARP inhibitor talazoparib until it was sold to
Medivation, Inc. and ultimately commercialized by Pfizer, Inc.
following the $14 billion acquisition of Medivation, Inc.
Positions prior to LEAD included senior vice president of research
and development for Onyx Pharmaceuticals and vice president of
discovery research for Parke-Davis Pharmaceuticals. Dr. Post holds
a doctorate in biochemistry from the University of
Wisconsin and a B.S. in Chemistry from the University of
Michigan.
Neil Sankar, MD received his training in
clinical research and tumor biology from NCI Bethesda Maryland and
since has held Clinical development positions within leading
Biotech/Pharma including Genentech, Medimmune, Pharmacyclis,
Fiveprime, Otsuka, Portola, CBT Pharmaceuticals, LSK biopharma and
Rhizen Pharmaceuticals. As an expert in providing global clinical
development and regulatory strategies for therapeutic drugs, Dr
Sankar has acted as clinical lead in numerous phase I, II and III
clinical trials. He is and was instrumental in filing the New Drug
Applications for the antibody-drug conjugate Kadcyla and the B cell
receptor signaling kinase inhibitor Ibrutinib. He has extensive
experience in the application of US Food and Drug Administration
regulations and the Good Clinical Practice guidelines set forth by
the International Council on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use. Dr.
Sankar is an active member of the American Society of Clinical
Oncology (ASCO), the American Society of Hematology (ASH), the
European Hematology Association (EHA), Drug information association
(DIA), European society of clinical oncology (ESMO), American
association for cancer research (AACR), Enterprising Pharmaceutical
Professionals from the Indian Sub-Continent (EPPIC GLOBAL),
Connective Tissue Oncology Society (CTOS), and TiE Silicon
Valley. Neil Sankar received his MD degree
from Bangalore university and internal medicine residency
from Univ of West indies, Kingston, Jamaica and trained
in UK and the Caribbean. He also holds a postgraduate degree
in public health from Queensland
University in Australia.
Wang Shen, PhD is the inventor of the
kt-2000, kt-3000 and kt-4000 families of drug candidates under
development by Rakovina Therapeutics. Dr. Shen is founder and chief
executive officer of Viva Vision Biotech, an ophthalmology company
based in Shanghai, China. Dr. Shen has more than 20 years of
drug discovery and project management experiences in large
pharmaceutical companies such as Abbott, Amgen, Sunesis and
Kanion USA. He is the principal inventor of
Lifitegrast (SAR1118), a potent LFA-1 inhibitor, approved by
FDA to treat dry eye disease. He also made an important
contribution to Venetoclax (ABT-199/GDC-0199), a selective BCL-2
inhibitor, approved by FDA in 2016 to treat certain types of
leukemia. He is the co-author of over 40 peer-reviewed publications
and co-inventor of over 40 patents. Dr. Shen received his B.S. in
chemistry from Fudan University and Ph.D. in Organic Chemistry
from Pittsburgh University with Professor Dennis P.
Curran. Dr. Shen completed his postdoctoral training in Memorial
Sloan-Kettering Cancer Center with Prof. Samuel J.
Danishefsky.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. was established in 2020 to develop
new cancer treatments based on novel DNA-damage response
technologies. The Company has established a pipeline of
DNA-damage response inhibitors with the goal of advancing one or
more drug candidates into human clinical trials and obtaining
marketing approval for new cancer therapeutics from Health Canada,
the United States Food and Drug Administration and similar
international regulatory agencies. Further information may be
found at www.rakovinatherapeutics.com.
Additional Information
The TSXV has neither approved nor disapproved the content of
this press release. Neither the TSXV nor its Regulation Services
Provider (as that term is defined in policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this
release.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding
the Company and its respective business, which may include, but is
not limited to, statements with respect to the proposed business
plan of the Company and other statements. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events, or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of the
Company. The forward-looking events and circumstances discussed in
this release may not occur by certain specified dates or at all and
could differ materially as a result of known and unknown risk
factors and uncertainties affecting the Company, including risks
regarding the medical device industry, economic factors, regulatory
factors, the equity markets generally and risks associated with
growth and competition. Although the Company has
attempted to identify important factors that could cause actual
actions, events, or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events, or results to differ from those
anticipated, estimated or intended. No forward-looking statement
can be guaranteed. Except as required by applicable securities
laws, forward-looking statements speak only as of the date on which
they are made and the Company undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result
of new information, future events, or
otherwise. The reader is referred to the
Company's most recent filings on SEDAR for a more complete
discussion of all applicable risk factors and their potential
effects, copies of which may be accessed through the Company's
profile page at www.sedar.com.
SOURCE Rakovina Therapeutics Inc.
For further information: Rakovina Therapeutics Inc.: David
Hyman, Chief Financial Officer, Email: info@rakovinatherapeutics.com;
Investor Relations Contact: IR@rakovinatherapeutics.com;
Media Contact: MEDIA@rakovinatherapeutics.com
Rakovina Therapeutics (TSXV:RKV)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Rakovina Therapeutics (TSXV:RKV)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
